The laboratory tests segment by diagnosis is estimated to lead the market growth during the forecast period.

According to a new market research study of “North America Irritable Bowel Syndrome (IBS) Diagnostics Market Forecast to 2028 - COVID-19 Impact and Regional Analysis by Diagnosis, Indication and Country.” The North America irritable bowel syndrome (IBS) diagnostics market is expected to reach US$ 1,529.08 million by 2028 from US$ 950.83 million in 2020; it is estimated to grow at a CAGR of 6.2% from 2021 to 2028. The report highlights trends prevailing in the North America irritable bowel syndrome (ibs) diagnostics market and the factors driving market along with those that act as hindrances.

The North America irritable bowel syndrome (IBS) diagnostics market based on the diagnosis was segmented into laboratory tests and imaging tests. In 2020, the laboratory tests segment held the largest share of the market, and same segment is expected to grow at the fastest rate during the coming years. Irritable bowel syndrome is a chronic gastrointestinal condition that is caused due to disturbances in bowel habits and abdominal pain. People across the world are witnessing considerable incidence of irritable bowel syndrome. Certain factors such as food allergies, developing stages of gastroenteritis, sporadic movements of colon, abnormal composition of serotonin in colon, and mild celiac disease are among the risk factors that cause irritable bowel syndrome. According to a study published on NCBI in 2018, irritable bowel syndrome is estimated to affect around 10%–16% of the US population each year. Such staggering prevalence of irritable bowel syndrome is likely to boost the irritable bowel syndrome (IBS) diagnostics market during the forecast period. To cope up against irritable bowel syndrome, the companies involved in the drug development for irritable bowel syndrome are taking constructive steps to create awareness programs with an aim to spread awareness amongst the population. Such initiatives are anticipated to drive the growth of the irritable bowel syndrome (IBS) diagnostics market. Also, increasing number of FDA approvals and diagnostics development activities are likely to accelerate the growth of the irritable bowel syndrome (IBS) diagnostics market during the forecast period.

The growth of the market is determined due to some of the key driving factors, such as increasing prevalence of irritable bowel syndrome and associated conditions and advancements in diagnostics of syndrome. On the other hand, challenges in diagnosis of IBS are likely to restraint the growth of market during the forecast years.

Commonwealth Diagnostics International, Genova Diagnostics, Gemelli Biotech, Prometheus Laboratories, Inova Diagnostics, Inc, Biohit Oyj, Aerodiagnostics, LLC., Metabolic Solutions, Inc, Sysmex Corporation (Sysmex Europe GmbH), and BÜHLMANN Laboratories AG are among the leading companies operating in the North America irritable bowel syndrome (IBS) diagnostics market.

The report segments in North America Irritable Bowel Syndrome (IBS) Diagnostics Market as follows:

By Diagnosis

• Laboratory Tests
  • Lactose Intolerance Tests
  • Breath Test for Bacterial Overgrowth
  • Stool Tests
  • Blood Tests
• Imaging Tests
  • CT Scan or X-ray
  • Upper Endoscopy
  • Colonoscopy

By Indication

• Pain and Cramping
• Diarrhea
• Constipation
• Alternating Constipation & Diarrhea

By Country

• US
• Canada
• Mexico